Literature DB >> 33392273

A Disintegrin and Metalloproteinase-Control Elements in Infectious Diseases.

Ahmad Aljohmani1, Daniela Yildiz1.   

Abstract

Despite recent advances in treatment strategies, infectious diseases are still under the leading causes of death worldwide. Although the activation of the inflammatory cascade is one prerequisite of defense, persistent and exuberant immune response, however, may lead to chronicity of inflammation predisposing to a temporal or permanent tissue damage not only of the site of infection but also among different body organs. The initial response to invading pathogens is mediated by the recognition through various pattern-recognition receptors along with cellular engulfment resulting in a coordinated release of soluble effector molecules and cytokines aiming to terminate the external stimuli. Members of the 'a disintegrin and metalloproteinase' (ADAM) family have the capability to proteolytically cleave transmembrane molecules close to the plasma membrane, a process called ectodomain shedding. In fact, in infectious diseases dysregulation of numerous ADAM substrates such as junction molecules (e.g., E-cadherin, VE-cadherin, JAM-A), adhesion molecules (e.g., ICAM-1, VCAM-1, L-selectin), and chemokines and cytokines (e.g., CXCL16, TNF-α) has been observed. The alpha-cleavage by ADAM proteases represents a rate limiting step for downstream regulated intramembrane proteolysis (RIPing) of several substrates, which influence cellular differentiation, cell signaling pathways and immune modulation. Both the substrates mentioned above and RIPing crucially contribute to a systematic damage in cardiovascular, endocrine, and/or gastrointestinal systems. This review will summarize the current knowledge of ADAM function and the subsequent RIPing in infectious diseases (e.g., pathogen recognition and clearance) and discuss the potential long-term effect on pathophysiological changes such as cardiovascular diseases.
Copyright © 2020 Aljohmani and Yildiz.

Entities:  

Keywords:  SARS – CoV; cardiovascular; infection; metalloproteinase; regulated intramembrane proteolysis

Year:  2020        PMID: 33392273      PMCID: PMC7772189          DOI: 10.3389/fcvm.2020.608281

Source DB:  PubMed          Journal:  Front Cardiovasc Med        ISSN: 2297-055X


  7 in total

1.  Simultaneous detection of multiple proteases using a non-array nanopore platform.

Authors:  Xiaohan Chen; Youwen Zhang; Xiyun Guan
Journal:  Nanoscale       Date:  2021-08-03       Impact factor: 8.307

2.  Contribution of Puma to Inflammatory Resolution During Early Pneumococcal Pneumonia.

Authors:  Daniel E Kennedy Ii; Perceus Mody; Jean-Francois Gout; Wei Tan; Keun Seok Seo; Alicia K Olivier; Jason W Rosch; Justin A Thornton
Journal:  Front Cell Infect Microbiol       Date:  2022-05-26       Impact factor: 6.073

Review 3.  TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy.

Authors:  Hui Qiu; Zhiying Shao; Xin Wen; Jinghua Jiang; Qinggong Ma; Yan Wang; Long Huang; Xin Ding; Longzhen Zhang
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

4.  Pseudomonas aeruginosa Triggered Exosomal Release of ADAM10 Mediates Proteolytic Cleavage in Trans.

Authors:  Ahmad Aljohmani; Bastian Opitz; Markus Bischoff; Daniela Yildiz
Journal:  Int J Mol Sci       Date:  2022-01-23       Impact factor: 5.923

Review 5.  Impact of SARS-CoV-2 on Host Factors Involved in Mental Disorders.

Authors:  Raina Rhoades; Sarah Solomon; Christina Johnson; Shaolei Teng
Journal:  Front Microbiol       Date:  2022-04-04       Impact factor: 6.064

6.  Pseudomonas aeruginosa Alters Critical Lung Epithelial Cell Functions through Activation of ADAM17.

Authors:  Ahmad Aljohmani; Noah Niklas Andres; Daniela Yildiz
Journal:  Cells       Date:  2022-07-26       Impact factor: 7.666

Review 7.  ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease.

Authors:  Francesca Tosetti; Massimo Alessio; Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.